Creo Medical Group (LON:CREO) Shares Down 12.4% – Should You Sell?

Creo Medical Group PLC (LON:CREO)’s stock price fell 12.4% on Wednesday. The company traded as low as GBX 9.90 and last traded at GBX 10.40. Approximately 7,994,368 shares changed hands during trading, an increase of 921% from the average daily volume of 783,030 shares. The stock had previously closed at GBX 11.88.

Analyst Ratings Changes

Separately, Shore Capital Group reiterated a “house stock” rating and issued a GBX 40 target price on shares of Creo Medical Group in a research note on Thursday, July 23rd.

Creo Medical Group Stock Performance

The stock has a market capitalization of £50.52 million, a P/E ratio of 10.40 and a beta of 1.56. The company has a quick ratio of 2.19, a current ratio of 3.22 and a debt-to-equity ratio of 8.20. The company has a 50-day moving average price of GBX 12.77 and a two-hundred day moving average price of GBX 12.87.

Creo Medical Group (LON:CREO) last released its quarterly earnings data on Wednesday, September 30th. The company reported GBX (2) EPS for the quarter. Creo Medical Group had a net margin of 88.33% and a return on equity of 9.56%. Equities analysts expect that Creo Medical Group PLC will post -10.0800005 earnings per share for the current year.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.